ReviewTrends in cardiovascular medicine2016
Stem cell therapy for heart failure: Ensuring regenerative proficiency.
Review in Trends in cardiovascular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial.Stem cells translational medicine · 2024Trial
- Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.European heart journal · 2017Trial
- Review
- Global Healthspan-Lifespan Gaps Among 183 World Health Organization Member States.JAMA network open · 2024Article
- Decoded cardiopoietic cell secretome linkage to heart repair biosignature.Stem cells translational medicine · 2024Article
- Optimized Catheter System Demonstrates Utility for Endomyocardial Delivery of Cardiopoietic Stem Cells in Target Patients With Heart Failure.Texas Heart Institute journal · 2023Article
- Isoproterenol pre-treatment improve the therapeutic efficacy of cardiosphere-derived cells transplantation for myocardial infarction.Journal of thoracic disease · 2023Article
- Extracellular Vesicles from NMN Preconditioned Mesenchymal Stem Cells Ameliorated Myocardial Infarction via miR-210-3p Promoted Angiogenesis.Stem cell reviews and reports · 2023Article
- Article
- Mass Customized Outlook for Regenerative Heart Failure Care.International journal of molecular sciences · 2021Review
- Longevity leap: mind the healthspan gap.NPJ Regenerative medicine · 2021Review
- Secretome signature of cardiopoietic cells echoed in rescued infarcted heart proteome.Stem cells translational medicine · 2021Article
- 3D bioprinting of stem cell-laden cardiac patch: A promising alternative for myocardial repair.APL bioengineering · 2021Review
- Molecular Imaging Using Cardiac PET/CT: Opportunities to Harmonize Diagnosis and Therapy.Current cardiology reports · 2021Review
- Screening for regenerative therapy responders in heart failure.Biomarkers in medicine · 2021Review
- Multiplexed targeting of miRNA-210 in stem cell-derived extracellular vesicles promotes selective regeneration in ischemic hearts.Experimental & molecular medicine · 2021Article
- Brachyury engineers cardiac repair competent stem cells.Stem cells translational medicine · 2021Article
- Cardiac Derived CD51-Positive Mesenchymal Stem Cells Enhance the Cardiac Repair Through SCF-Mediated Angiogenesis in Mice With Myocardial Infarction.Frontiers in cell and developmental biology · 2021Article
- Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome.NPJ Regenerative medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
Patient-derived stem cells enable promising regenerative strategies, but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardio-regenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.